Correction to: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial (Nature Medicine, (2025), 31, 6, (1987-1993), 10.1038/s41591-025-03640-8)

Yago Nieto; Pinaki Banerjee; Indreshpal Kaur; Rafet Basar; Ye Li; May Daher; Hind Rafei; Lucila N. Kerbauy; Mecit Kaplan; David Marin; Lori Griffin; Melissa Barnett; Roland Bassett; Nadima Uprety; Rejeena Shrestha; Francia Reyes Silva; Sanjida Islam; Christina Ganesh; Zephanie Borneo; Jeremy Ramdial; Alejandro Ramirez; Chitra Hosing; Amin Alousi; Uday Popat; Muzaffar Qazilbash; Sairah Ahmed; Swaminathan Iyer; Tania P. Sainz; Francisco Vega; Natalie W. Fowlkes; Karenza Alexis; Michael Emig; Andreas Harstrick; Andre Overesch; Elizabeth J. Shpall; Katayoun Rezvani

doi:10.1038/s41591-025-03852-y

Correction to: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial (Nature Medicine, (2025), 31, 6, (1987-1993), 10.1038/s41591-025-03640-8)

Yago Nieto
, Pinaki Banerjee
, Indreshpal Kaur
, Rafet Basar
, Ye Li
, May Daher
, Hind Rafei
, Lucila N. Kerbauy
, Mecit Kaplan
, David Marin
, Lori Griffin
, Melissa Barnett
, Roland Bassett
, Nadima Uprety
, Rejeena Shrestha
, Francia Reyes Silva
, Sanjida Islam
, Christina Ganesh
, Zephanie Borneo
, Jeremy Ramdial

Alejandro Ramirez, Chitra Hosing, Amin Alousi, Uday Popat, Muzaffar Qazilbash, Sairah Ahmed, Swaminathan Iyer, Tania P. Sainz, Francisco Vega, Natalie W. Fowlkes, Karenza Alexis, Michael Emig, Andreas Harstrick, Andre Overesch, Elizabeth J. Shpall, Katayoun Rezvani

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-025-03640-8, published online 4 April 2025. In the version of this article initially published, there were typographical errors in the units listed in the Methods “Manufacturing of AFM13-NK cells from CB” section, where in the text now reading “The NK cells were enriched … followed by preactivation for 16 h with 10 ng ml IL-12 (Miltenyi Biotec), 50 ng ml⁻¹ IL-15 (R&D Systems) and 50 ng ml⁻¹ IL-18 (R&D Systems),” “µg” appeared instead of “ng” in three places. The errors have been corrected in the HTML and PDF versions of the article.

Original language	English (US)
Pages (from-to)	2816
Number of pages	1
Journal	Nature medicine
Volume	31
Issue number	8
DOIs	https://doi.org/10.1038/s41591-025-03852-y
State	Published - Aug 2025

ASJC Scopus subject areas

General Medicine
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/s41591-025-03852-y

Cite this

Nieto, Y., Banerjee, P., Kaur, I., Basar, R., Li, Y., Daher, M., Rafei, H., Kerbauy, L. N., Kaplan, M., Marin, D., Griffin, L., Barnett, M., Bassett, R., Uprety, N., Shrestha, R., Silva, F. R., Islam, S., Ganesh, C., Borneo, Z., ... Rezvani, K. (2025). Correction to: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial (Nature Medicine, (2025), 31, 6, (1987-1993), 10.1038/s41591-025-03640-8). Nature medicine, 31(8), 2816. https://doi.org/10.1038/s41591-025-03852-y

Correction to: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial (Nature Medicine, (2025), 31, 6, (1987-1993), 10.1038/s41591-025-03640-8). / Nieto, Yago ; Banerjee, Pinaki; Kaur, Indreshpal et al.
In: Nature medicine, Vol. 31, No. 8, 08.2025, p. 2816.

Research output: Contribution to journal › Comment/debate › peer-review

Nieto, Y , Banerjee, P, Kaur, I, Basar, R , Li, Y , Daher, M , Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, J, Ramirez, A, Hosing, C , Alousi, A , Popat, U , Qazilbash, M , Ahmed, S , Iyer, S, Sainz, TP, Vega, F , Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, EJ & Rezvani, K 2025, 'Correction to: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial (Nature Medicine, (2025), 31, 6, (1987-1993), 10.1038/s41591-025-03640-8)', Nature medicine, vol. 31, no. 8, pp. 2816. https://doi.org/10.1038/s41591-025-03852-y

@article{5b54d9c2416342c7a0a8180e651545d6,

title = "Correction to: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial (Nature Medicine, (2025), 31, 6, (1987-1993), 10.1038/s41591-025-03640-8)",

abstract = "Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-025-03640-8, published online 4 April 2025. In the version of this article initially published, there were typographical errors in the units listed in the Methods “Manufacturing of AFM13-NK cells from CB” section, where in the text now reading “The NK cells were enriched … followed by preactivation for 16 h with 10 ng ml IL-12 (Miltenyi Biotec), 50 ng ml−1 IL-15 (R\&D Systems) and 50 ng ml−1 IL-18 (R\&D Systems),” “µg” appeared instead of “ng” in three places. The errors have been corrected in the HTML and PDF versions of the article.",

author = "Yago Nieto and Pinaki Banerjee and Indreshpal Kaur and Rafet Basar and Ye Li and May Daher and Hind Rafei and Kerbauy, \{Lucila N.\} and Mecit Kaplan and David Marin and Lori Griffin and Melissa Barnett and Roland Bassett and Nadima Uprety and Rejeena Shrestha and Silva, \{Francia Reyes\} and Sanjida Islam and Christina Ganesh and Zephanie Borneo and Jeremy Ramdial and Alejandro Ramirez and Chitra Hosing and Amin Alousi and Uday Popat and Muzaffar Qazilbash and Sairah Ahmed and Swaminathan Iyer and Sainz, \{Tania P.\} and Francisco Vega and Fowlkes, \{Natalie W.\} and Karenza Alexis and Michael Emig and Andreas Harstrick and Andre Overesch and Shpall, \{Elizabeth J.\} and Katayoun Rezvani",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature America, Inc. 2025.",

year = "2025",

month = aug,

doi = "10.1038/s41591-025-03852-y",

language = "English (US)",

volume = "31",

pages = "2816",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "8",

}

TY - JOUR

T1 - Correction to

T2 - Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial (Nature Medicine, (2025), 31, 6, (1987-1993), 10.1038/s41591-025-03640-8)

AU - Nieto, Yago

AU - Banerjee, Pinaki

AU - Kaur, Indreshpal

AU - Basar, Rafet

AU - Li, Ye

AU - Daher, May

AU - Rafei, Hind

AU - Kerbauy, Lucila N.

AU - Kaplan, Mecit

AU - Marin, David

AU - Griffin, Lori

AU - Barnett, Melissa

AU - Bassett, Roland

AU - Uprety, Nadima

AU - Shrestha, Rejeena

AU - Silva, Francia Reyes

AU - Islam, Sanjida

AU - Ganesh, Christina

AU - Borneo, Zephanie

AU - Ramdial, Jeremy

AU - Ramirez, Alejandro

AU - Hosing, Chitra

AU - Alousi, Amin

AU - Popat, Uday

AU - Qazilbash, Muzaffar

AU - Ahmed, Sairah

AU - Iyer, Swaminathan

AU - Sainz, Tania P.

AU - Vega, Francisco

AU - Fowlkes, Natalie W.

AU - Alexis, Karenza

AU - Emig, Michael

AU - Harstrick, Andreas

AU - Overesch, Andre

AU - Shpall, Elizabeth J.

AU - Rezvani, Katayoun

PY - 2025/8

Y1 - 2025/8

N2 - Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-025-03640-8, published online 4 April 2025. In the version of this article initially published, there were typographical errors in the units listed in the Methods “Manufacturing of AFM13-NK cells from CB” section, where in the text now reading “The NK cells were enriched … followed by preactivation for 16 h with 10 ng ml IL-12 (Miltenyi Biotec), 50 ng ml−1 IL-15 (R&D Systems) and 50 ng ml−1 IL-18 (R&D Systems),” “µg” appeared instead of “ng” in three places. The errors have been corrected in the HTML and PDF versions of the article.

AB - Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-025-03640-8, published online 4 April 2025. In the version of this article initially published, there were typographical errors in the units listed in the Methods “Manufacturing of AFM13-NK cells from CB” section, where in the text now reading “The NK cells were enriched … followed by preactivation for 16 h with 10 ng ml IL-12 (Miltenyi Biotec), 50 ng ml−1 IL-15 (R&D Systems) and 50 ng ml−1 IL-18 (R&D Systems),” “µg” appeared instead of “ng” in three places. The errors have been corrected in the HTML and PDF versions of the article.

UR - https://www.scopus.com/pages/publications/105010890067

UR - https://www.scopus.com/pages/publications/105010890067#tab=citedBy

U2 - 10.1038/s41591-025-03852-y

DO - 10.1038/s41591-025-03852-y

M3 - Comment/debate

C2 - 40571757

AN - SCOPUS:105010890067

SN - 1078-8956

VL - 31

SP - 2816

JO - Nature medicine

JF - Nature medicine

IS - 8

ER -

Correction to: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial (Nature Medicine, (2025), 31, 6, (1987-1993), 10.1038/s41591-025-03640-8)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this